Flexion Therapeutics (FLXN) Stock Price Down 0%
Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) traded down 0% on Tuesday . The company traded as low as $25.01 and last traded at $25.03. 813,194 shares changed hands during trading, an increase of 26% from the average session volume of 646,934 shares. The stock had previously closed at $25.03.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Northland Securities reiterated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a report on Friday, November 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Janney Montgomery Scott increased their price objective on Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $37.00 price objective (up previously from $35.00) on shares of Flexion Therapeutics in a report on Monday, October 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $106.25.
The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market cap of $939.65, a price-to-earnings ratio of -7.11 and a beta of 1.14.
In other news, insider Neil Bodick bought 2,700 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the transaction, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael D. Clayman bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the transaction, the insider now owns 35,395 shares in the company, valued at $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Berson & Corrado Investment Advisors LLC acquired a new position in shares of Flexion Therapeutics in the 4th quarter valued at $324,000. Highbridge Capital Management LLC increased its position in shares of Flexion Therapeutics by 408.2% in the 3rd quarter. Highbridge Capital Management LLC now owns 50,823 shares of the specialty pharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 40,823 shares during the period. Gagnon Securities LLC acquired a new position in shares of Flexion Therapeutics in the 3rd quarter valued at $3,490,000. Uniplan Investment Counsel Inc. acquired a new position in shares of Flexion Therapeutics in the 3rd quarter valued at $2,996,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Flexion Therapeutics by 6.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 107,550 shares of the specialty pharmaceutical company’s stock valued at $2,601,000 after acquiring an additional 6,336 shares during the period. 72.78% of the stock is currently owned by hedge funds and other institutional investors.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.